Literature DB >> 11472732

The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans.

T Demant1, K Seeberg, A Bedynek, D Seidel.   

Abstract

Lipoprotein(a) is a risk factor for cardiovascular disease composed of an apolipoprotein B-containing lipoprotein to which a second protein, apolipoprotein(a), is attached. We investigated in seven subjects with Lp(a) levels of 39--85 mg/dl the metabolism of four apo B-containing lipoproteins (VLDL(1), VLDL(2), IDL and LDL) together with that of apo B and apo(a) isolated from Lp(a). Rates of secretion, catabolism and where appropriate, transfer were determined by intravenous administration of d(3)-leucine, mass spectrometry for measurements of leucine tracer/tracee ratios and kinetic data analysis using multicompartmental metabolic modeling. Apo B in Lp(a) was secreted at a rate of 0.28 (0.17--0.40) mg/kg per day. It was found to originate from two sources -- 53% (43--67) were derived from preformed lipoproteins, i.e. IDL and LDL, the remainder was accounted for by apo B, directly secreted by the liver. The fractional catabolic rates (FCRs) of apo B and of apo(a) prepared from Lp(a) were determined as 0.27 (0.16--0.38) and 0.24 (0.12--0.40) pools per day, respectively, which is less than half of the FCR observed for LDL. Our in vivo data from humans support the view that Lp(a) assembly is an extracellular process and that its two protein components, apo(a) and apo B, are cleared from the circulation at identical rates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472732     DOI: 10.1016/s0021-9150(00)00732-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

Review 1.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

Review 2.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

3.  Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Lars Berglund
Journal:  Atherosclerosis       Date:  2014-05-10       Impact factor: 5.162

4.  Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).

Authors:  Justin R Clark; Matthew Gemin; Amer Youssef; Santica M Marcovina; Annik Prat; Nabil G Seidah; Robert A Hegele; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2022-04-22       Impact factor: 6.676

5.  Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).

Authors:  Margaret R Diffenderfer; Stefania Lamon-Fava; Santica M Marcovina; P Hugh R Barrett; Julian Lel; Gregory G Dolnikowski; Lars Berglund; Ernst J Schaefer
Journal:  Metabolism       Date:  2015-11-06       Impact factor: 8.694

Review 6.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

7.  Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry.

Authors:  Haihong Zhou; Jose Castro-Perez; Michael E Lassman; Tiffany Thomas; Wenyu Li; Theresa McLaughlin; Xie Dan; Patricia Jumes; John A Wagner; David E Gutstein; Brian K Hubbard; Daniel J Rader; John S Millar; Henry N Ginsberg; Gissette Reyes-Soffer; Michele Cleary; Stephen F Previs; Thomas P Roddy
Journal:  Rapid Commun Mass Spectrom       Date:  2013-06-30       Impact factor: 2.419

Review 8.  Lipoprotein (a): When to Measure and How to Treat?

Authors:  David Rhainds; Mathieu R Brodeur; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2021-07-08       Impact factor: 5.113

9.  Effects of renal replacement therapy on plasma lipoprotein(a) levels.

Authors:  Sylvia Rosas; Marshall Joffe; Megan Wolfe; Kenneth Brayman; Daniel J Rader
Journal:  Am J Nephrol       Date:  2007-12-05       Impact factor: 3.754

Review 10.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.